Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ronopterin - vasopharm BIOTECH

Drug Profile

Ronopterin - vasopharm BIOTECH

Alternative Names: VAS-203

Latest Information Update: 31 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator vasopharm BIOTECH
  • Class Neuroprotectants; Pteridines; Small molecules
  • Mechanism of Action Nitric oxide synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Brain injuries

Most Recent Events

  • 11 Jul 2019 vasopharm BIOTECH announces intention to submit MAA to EMA for Brain Injuries
  • 21 Jun 2019 Pharmacokinetic data from a phase I trial in renal function and perfusion in Healthy volunteers presented at the 29th European Meeting on Hypertension and Cardiovascular Protection (ESH-2019)
  • 15 Mar 2018 Adverse events data from a phase I trial in Brain injuries released by vasopharm BIOTECH (NCT02992236)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top